Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

[1]  R. Nicholson,et al.  Nonendocrine Pathways and Endocrine Resistance , 2004, Clinical Cancer Research.

[2]  R. Nicholson,et al.  The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. , 2003, Endocrinology.

[3]  R. Roth,et al.  Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  J. Woodgett,et al.  Unravelling the activation mechanisms of protein kinase B/Akt , 2003, FEBS letters.

[5]  G. Giaccone,et al.  Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[7]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[8]  Olle Stål,et al.  Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.

[9]  J. Woodgett,et al.  Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B , 2002, Molecular and Cellular Biology.

[10]  C. Arteaga,et al.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.

[11]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[12]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[13]  B. Hemmings,et al.  Inhibition of protein kinase B/Akt. implications for cancer therapy. , 2002, Pharmacology & therapeutics.

[14]  R. Glazer,et al.  Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. , 2001, Cancer research.

[15]  N. Rosen,et al.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.

[16]  H. Koh,et al.  Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  R. Nicholson,et al.  Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. , 2001, Endocrine-related cancer.

[18]  J E Paciga,et al.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.

[19]  Z. Lu,et al.  AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[21]  R. Nicholson,et al.  Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.

[22]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[23]  B. Katzenellenbogen,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I* , 2000 .

[24]  Y. Chiew,et al.  Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines , 2000, International journal of cancer.

[25]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[26]  S. Ethier,et al.  Heregulin‐β is especially potent in activating phosphatidylinositol 3‐kinase in nontransformed human mammary epithelial cells , 2000 .

[27]  Domenico Coppola,et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.

[28]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[29]  J. Segall,et al.  Specific Requirement for the p85-p110α Phosphatidylinositol 3-Kinase during Epidermal Growth Factor-stimulated Actin Nucleation in Breast Cancer Cells* , 2000, The Journal of Biological Chemistry.

[30]  E. Kandel,et al.  The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. , 1999, Experimental cell research.

[31]  P. Cohen,et al.  Role of protein kinase B and the MAP kinase cascade in mediating the EGF‐dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells 1 , 1999 .

[32]  W. Liu,et al.  Heregulin regulation of Akt/protein kinase B in breast cancer cells. , 1999, Biochemical and biophysical research communications.

[33]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[34]  Monilola A. Olayioye,et al.  ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.

[35]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Cohen,et al.  Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.

[37]  D R Alessi,et al.  Mitogenic Activation, Phosphorylation, and Nuclear Translocation of Protein Kinase Bβ* , 1997, The Journal of Biological Chemistry.

[38]  M. Dowsett,et al.  Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[40]  E. Dmitrovsky,et al.  The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. , 1996, Cytokine & growth factor reviews.

[41]  R. Lupu,et al.  Involvement of Heregulin-β2 in the Acquisition of the Hormone-independent Phenotype of Breast Cancer Cells , 1996 .

[42]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[44]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[45]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Lynch,et al.  Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. , 1992, British Journal of Cancer.

[47]  M. Toi,et al.  Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. , 1991, European journal of cancer.

[48]  M. Kraus,et al.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.

[49]  R. Shoemaker,et al.  A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. , 1988, Molecular endocrinology.

[50]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Nicholson,et al.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839) , 2004, Clinical & Experimental Metastasis.

[52]  I. Ellis,et al.  Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.

[53]  B. Karlan,et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.

[54]  M. Dowsett,et al.  Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  M. Dowsett,et al.  Enhanced ERα, ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term oestrogen deprivation , 2003 .

[56]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[57]  M. C. Hu,et al.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. , 2000, The Journal of biological chemistry.

[58]  S. Ethier,et al.  Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. , 2000, Journal of cellular physiology.

[59]  P. Cohen,et al.  Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. , 1999, FEBS letters.

[60]  A. Wells.  EGF receptor. , 1999, The international journal of biochemistry & cell biology.

[61]  R. Lupu,et al.  Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. , 1996, Cancer research.